2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[2] - The net profit attributable to shareholders for the same period was RMB 260,913,556.78, showing a significant increase of 176.77% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, up 195.97% compared to the previous year[2] - The basic earnings per share for Q3 2022 was RMB 0.49, an increase of 88.46% year-on-year[4] - The company's revenue for the current reporting period increased by 55.01%, primarily due to business growth[11] - The net profit attributable to shareholders for the current reporting period rose by 176.77%, driven by business growth and the appreciation of biological assets[11] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 195.97% in the current reporting period, attributed to business growth and biological asset appreciation[11] - The basic earnings per share for the current reporting period reached 88.46 RMB, reflecting significant business growth[11] - The net profit for Q3 2022 was approximately CNY 630.97 million, a significant increase from CNY 247.01 million in Q3 2021, representing a growth of 155.5%[21] - The total revenue from operating activities for the first three quarters of 2022 reached CNY 1.98 billion, compared to CNY 1.39 billion in the same period of 2021, indicating a year-over-year increase of 42.5%[23] - The operating profit for Q3 2022 was CNY 717.78 million, up from CNY 281.54 million in Q3 2021, marking a growth of 154.1%[21] - The total comprehensive income for Q3 2022 was CNY 666.16 million, compared to CNY 245.57 million in Q3 2021, which is an increase of 171.5%[22] - Basic earnings per share for Q3 2022 were CNY 1.18, up from CNY 0.68 in Q3 2021, representing a growth of 73.5%[22] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a 67.93% increase year-on-year[2] - The cash flow from operating activities for Q3 2022 was CNY 778.29 million, compared to CNY 463.45 million in Q3 2021, reflecting an increase of 77.5%[24] - The company's cash and cash equivalents decreased from approximately 4.15 billion RMB at the end of 2021 to about 2.87 billion RMB by September 30, 2022[15] - The cash and cash equivalents at the end of Q3 2022 were CNY 2.85 billion, down from CNY 4.11 billion at the end of Q3 2021, a decrease of 30.5%[25] - The net cash flow from investing activities for Q3 2022 was negative CNY 2.03 billion, compared to negative CNY 1.89 billion in Q3 2021, indicating a worsening of cash outflow[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an 18.06% increase from the end of the previous year[4] - The company's total assets as of the end of the third quarter of 2022 were ¥10,079,078,937.04, an increase from ¥8,537,077,111.40 at the end of the previous year, representing a growth of about 18%[18] - Total liabilities increased to ¥2,408,488,539.00 in the third quarter of 2022, compared to ¥1,392,640,954.56 in the same period last year, marking an increase of approximately 73%[18] - The company's total equity reached ¥7,670,590,398.04, up from ¥7,144,436,156.84 in the previous year, indicating a growth of about 7.4%[18] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, reflecting a growth of approximately 43%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,275[12] - The largest shareholder, Feng Yuxia, holds 22.31% of the shares[13] Government Subsidies and Acquisitions - The government subsidies received during the year-to-date amounted to RMB 8,457,000, down from RMB 23,608,000 in the same period last year[5] - The company has made acquisitions of Yunnan Yingmao Biotechnology Co., Ltd. and Guangxi Weimei Biotechnology Co., Ltd., resulting in a negative goodwill of RMB 14,367,000[5] Market Outlook - The company has over 4.6 billion RMB in hand orders as of the reporting period, providing strong support for future performance growth[14] - The company plans to expand its market presence and invest in new technologies, although detailed strategies were not specified in the report[20]